Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

por Dubourg, Julie, Ueki, Kohjiro, Grouin, Jean‐Marie, Fouqueray, Pascale
Publicado 2021

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐l...

por Dubourg, Julie, Fouqueray, Pascale, Quinslot, Damien, Grouin, Jean‐Marie, Kaku, Kohei
Publicado 2021

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial wit...

por Reilhac, Caroline, Dubourg, Julie, Thang, Carole, Grouin, Jean‐Marie, Fouqueray, Pascale, Watada, Hirotaka
Publicado 2022

Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial

por Henrotin, Yves, Cozannet, Romain Le, Fança-Berthon, Pascale, Truillet, Romain, Cohen-Solhal, Martine, DunnGalvin, Gillian, Grouin, Jean-Marie, Doolan, Andrea
Publicado 2022

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

por Fouqueray, Pascale, Bolze, Sebastien, Dubourg, Julie, Hallakou-Bozec, Sophie, Theurey, Pierre, Grouin, Jean-Marie, Chevalier, Clémence, Gluais-Dagorn, Pascale, Moller, David E., Cusi, Kenneth
Publicado 2021

Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study

por Maheu, Emmanuel, Cadet, Christian, Marty, Marc, Moyse, Dominique, Kerloch, Isabelle, Coste, Philippe, Dougados, Maxime, Mazières, Bernard, Spector, Tim D, Halhol, Hafid, Grouin, Jean-Marie, Lequesne, Michel
Publicado 2014

IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double‐blind, multi‐center cross‐over non‐inferiority study vs Kiovig®—The LIME Study...

por Léger, Jean‐Marc, Alfa Cissé, Ousmane, Cocito, Dario, Grouin, Jean‐Marie, Katifi, Haider, Nobile‐Orazio, Eduardo, Ouaja, Rabye, Pouget, Jean, Rajabally, Yusuf A., Sevilla, Teresa, Merkies, Ingemar S. J.
Publicado 2018

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

por Francois, Bruno, Lambden, Simon, Gibot, Sebastien, Derive, Marc, Olivier, Aurelie, Cuvier, Valerie, Witte, Stephan, Grouin, Jean-Marie, Garaud, Jean Jacques, Salcedo-Magguilli, Margarita, Levy, Mitchell, Laterre, Pierre-François
Publicado 2021

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

por François, Bruno, Lambden, Simon, Garaud, Jean-Jacques, Derive, Marc, Grouin, Jean-Marie, Asfar, Pierre, Darreau, Cédric, Mira, Jean-Paul, Quenot, Jean-Pierre, Lemarié, Jérémie, Mercier, Emmanuelle, Lacherade, Jean-Claude, Vinsonneau, Christophe, Fivez, Tom, Helms, Julie, Badie, Julio, Levy, Mitchell, Cuvier, Valérie, Salcedo-Magguilli, Margarita, Laszlo-Pouvreau, Anne-Lise, Laterre, Pierre-François, Gibot, Sébastien
Publicado 2023